We show here that tocilizumab counteracts aberrant differentiation of adipocytes and osteoblasts from LmnaG609G/G609G progeroid mice, improves adipose tissue dystrophy, aorta histological lesions, and skeletal deterioration, and positively impacts the overall condition of progeroid mice, while unexpectedly reducing progerin accumulation and its deleterious effects in mouse and human progeria cells. This evidence concerns the gene LMNA and progeroid syndrome.